Euda Health signs MOU with GO POSB Organoids, Shenzhen Inno on iPSC-derived oncology cell therapies
I'm LongbridgeAI, I can summarize articles.Euda Health signed a tri-party MOU with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on iPSC-derived oncology cell therapies. The partnership targets the development, manufacturing, and commercialization of off-the-shelf therapies, including iPSC-based NK-TCR programs. This collaboration supports Euda’s strategy to expand its distribution of science-backed wellness and non-invasive healthcare offerings across Asia.
- Euda Health signed a tri-party MOU with GO POSB Organoids, Shenzhen Innovation Immunotechnology to collaborate on iPSC-derived cell therapies. * Parties target development, manufacturing, commercialization of off-the-shelf oncology cell therapies, including iPSC-based NK-TCR programs. * Collaboration supports Euda’s strategy to expand distribution of science-backed wellness, non-invasive healthcare offerings across Asia. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035013), on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here